Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday. According to Zacks, “Although Alexion’s first-quarter results were disappointing, with the company missing both top- and bottom-line estimates, growth at the company continues to be driven by Soliris. Moreover, the launch of […]
